- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00832481
Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions
Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions in Newly Diagnosed Type 2 Diabetes Patients in China
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a 17 week, randomized, single center, open-label, parallel-group study to compare glucose excursions and other efficacy and safety parameters of repaglinide thrice daily or metformin thrice daily in newly diagnosed type 2 diabetes subjects in China.
Eligibility for participation will be determined by medical history, physical examination, and laboratory results obtained during a screening visit (see trail population). About 60 patients with newly diagnosed (within 6 months) type 2 diabetes and both insulin and oral antidiabetic drugs (OAD) naïve will be include in this study. All subjects will be given informed consent before starting any examination and test. Then the 24h blood glucose of each patient will be recorded by utilizing continue glucose monitor system (CGMS). Besides that, the following data of all subject will be collected: HbA1c, Fasting blood glucose, 2h postprandial blood glucose, fasting lipid profile, 2h postprandial lipid profile, fasting uric acid, 2h postprandial uric acid, fasting insulin and proinsulin, 2h postprandial insulin and proinsulin, fasting C peptide, 2h postprandial C peptide, fasting glucagon, 2h postprandial glucagon.
After baseline data are collected, eligible subjects will be randomized into each group at a 2:1 ratio (40 for repaglinide and 20 for metformin). IVGTT and hyperinsulinemic-euglycemic clamp will be done to 20 patients in repaglinide group and 10 patients in metformin group (less than 20% drop-off rate is acceptable for this study). Follow that, all patients will start to receive either repaglinide thrice daily (immediately before breakfast lunch, and dinner) or metformin thrice daily (after breakfast, lunch and dinner). The initial repaglinide doses will be based on HbA1c levels on the day of randomization (0.5 mg tid for HbA1c < 8% and 1 mg tid for HbA1c ≥ 8%); the initial dosage for metformin will be 0.5 g tid and this dosage will be kept until the end of this study.
Treatment diaries will be asked for every subject to record glucose levels (7 times per day and 2 days per week for the first three weeks, then 7 times per day and 1 day per week until the end of this study), diet and exercise, stress situation, hypoglycemic symptoms and so on. All patients will be followed by visiting clinic every week for the first three weeks, but only patients in repaglinide group will be titrated their doses. Dose adjustment should be aimed at achieving the following glycemic targets: fasting blood glucose: 4.4 - 6.0 mmol/L, 2h post prandial glucose 4.4 - 8.0 mmol/L. If above glycaemic target has not been achieved, repaglinide dose should be adjusted for every week (see Schematic diagram of trial design). The adjustment of repaglinide doses is based on the mean of blood glucose recorded in subject diaries. The doses of repaglinide before each meal may be different, depending on the recorded blood glucose concentrations. After three weeks titration for repaglinide (maximal dosage for repaglinide is 2 mg tid), the patients in this group will keep the optimal dosage for the next 12 weeks. Clinic visit will be conducted every four weeks after the period of dosages titration to collect information, such as hypoglycemia, adverse events and fasting blood glucose.
Complicated examinations will be repeated again after above 12 weeks treatments for both groups, including physical examination, electrocardiogram (ECG), CGMS, fasting and 2h post prandial glucose, concentration of insulin, proinsulin, C peptide, glucagon, uric acid and so on. IVGTT and hyperinsulinemic-euglycemic clamp will be repeated only for subjects who did that at the beginning of study. Data will be collected and analyzed.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chunlin Li, M.D & Ph.D
- Phone Number: +86-13661285276
- Email: lcl301@yahoo.com.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Recruiting
- PLA General Hospital
-
Contact:
- Dong Cai
- Phone Number: +86-10-66939246
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent obtained before any trial-related activities. (Trial- related activities are any procedure that would not have been performed during normal management of the subject.)
- Ages between 20-90 years
- BMI between 18.5 and 30 kg/m2
- Newly diagnosed type 2 diabetes. Type 2 diabetes is in accordance with WHO criteria 1999
- The history of diabetes less than 6 months
- HbA1c <10%.
- Only on diet and/or exercise, OAD or insulin naïve subjects
Exclusion Criteria:
- Any history of OAD or insulin therapy preceding this trial.
- Type 1 diabetic subjects, including LADA
- Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures (adequate contraceptive measures are sterilisation, IUD, oral contraceptives or barrier methods) before and/or during the trial.
- Impaired hepatic function (ALT > 2.5 times upper limit of local laboratories normal ranges)
- Impaired renal function, defined as serum creatinine ≥ 1.5 mg/dl.
- Use of systemic or inhaled glucocorticoids or other medication known to interfere with glucose metabolism.
- Recently had acute diabetic complications
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- Recently had operation, injury, inflammation and other stress conditions.
- Recently had cardiac disease as following:
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Repaglinide,tablet
|
Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
Other Names:
|
Active Comparator: Metformin, tablet
|
2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To investigate the effects of monotherapy of either repaglinide or metformin on glucose excursion after 3 months treatment in newly diagnosed type 2 diabetes patients in China
Time Frame: from Jan.01 2009 to Oct.30,2009
|
from Jan.01 2009 to Oct.30,2009
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chunlin Li, M.D&Ph.D, PLA General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NovoNorm 301 Chunlin Li
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Repaglinide
-
Dalim BioTech Co., Ltd.CompletedDiabetes Mellitus, Type 2Korea, Republic of
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesKorea, Republic of
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesKorea, Republic of
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesChina
-
Children's Hospital of PhiladelphiaWithdrawn
-
Arbelaez, Ana MariaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Novo... and other collaboratorsCompletedPancreatic Insufficiency | Cystic Fibrosis Related DiabetesUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesChina